Key Takeaways
- Flat quarter, margin resilience: Revenue was flat as softer therapy tailwinds and a CMO fire clipped growth, yet EBITDA margin still improved 290 bps to 31.2% on disciplined expense management.
- Oncology launch is live: All go-to-market activations are complete, the team is recruited, and the Zejula/Jemperli launch goes live this month, with revenue starting in Q2.
- Base business hit by two external shocks: A CMO fire cost 1.7% of sales (Calpol, OvaRex), while the derm and antibiotic portfolios faced significant market-wide volume softness; GSK held or gained share through both.
- Vaccines and specialty are the growth bridge: Shingrix prescriptions grew ~20% QoQ and the GTE exemption opens institutional segments; Trelegy and Nucala continue to build share.
- What to watch next quarter: Whether the derm and antibiotic volumes recover into peak season, the pace of oncology revenue contribution, and whether the NLEM price hike fully flows through.
Revenue Headwinds: A Flat Quarter Deconstructed
- CMO fire supply shock: A fire at a contract manufacturer disrupted Calpol and OvaRex supply through May-June, costing an estimated 1.7% of sales; management expects stabilization in July-August.
- Derm portfolio volume decline: The Vx portfolio (topical steroids) and Betnovate range suffered the most significant external hit in Q1, with significant volume declines; management notes recovery in the last few weeks and expects growth back in Q2.
- Antibiotic seasonality delayed: A delayed monsoon between April and June suppressed the antibiotic portfolio, with brands like Augmentin seeing flat or declining volumes; Augmentin still gained 0.4% market share in the quarter with an evolution index above 104.
- NLEM price hike timing: The price hike for NLEM products did not get full benefit in Q1; full realization is expected in Q2 and beyond.
- Competitive position intact: Despite muted market conditions, GSK grew ahead of the market in evolution index for both general medicines and vaccines, and held or gained share across key assets.
Bhushan Akshikar: "we have not only defended or gained market share for many of our key assets, but we have also grown ahead of the market in terms of evolution index both in general medicines as well as vaccines."
Oncology: The New Growth Platform Goes Live
- Launch timing and readiness: All go-to-market model activations and recruitment were completed in Q1; the team of ~20 key account specialists, a separate access team, and dedicated medical resources is in place; the launch goes live on Independence Day, with revenue starting in Q2.
- Two assets, two indications: Zejula (PARP inhibitor) is indicated for first-line ovarian cancer; Jemperli (PD-1 antagonist immunotherapy) currently has a second-line label for endometrial cancer in India, with the first-line approval in process.
- Jemperli pipeline depth: Ongoing clinical trials span at least four cancer types: head and neck, colorectal, and non-small cell lung.
- Cost structure contained: Incremental operating cost for oncology will not be material; costs will be reallocated from within existing accruals and reserves, with no additional data.
Bhushan Akshikar: "We go live on Independence Day. So, that is where our commitment in our first year of this second century of operation in India is to recommit ourselves to offer freedom to all those patients who deserve, who are unfortunately suffering from these gynecological malignancies and who can benefit with two innovative assets."
Vaccines & Specialty: The Steady Growth Engine
- Vaccine growth base sustained: The vaccine business has maintained 8%-10% growth over the last four quarters, with new segments opening up, particularly for shingles prevention.
- Shingrix momentum: Prescription growth was around 20% quarter-on-quarter; the recently obtained GTE exemption now allows participation in institutional segments such as the Army, railways, and other government accounts.
- Adult vaccination commitment: Management is putting more energy into building the adult vaccination ecosystem and is confident of maintaining or growing the current growth base.
- Specialty respiratory: Trelegy Ellipta continues to grow month after month; Nucala continues to grow in both market share and patient share.
- RSV vaccine on the horizon: Trials are ongoing; the launch is slated for calendar year 2026, not this financial year.
Bhushan Akshikar: "The adult vaccination ecosystem is an area where we remain committed and putting more energy. So, we are confident of maintaining or growing that growth base from here on."
Augmentin & Antibiotic Stewardship
- Market leadership defended: Augmentin remains the number one brand in the Indian pharma market; even in a non-peak quarter for the category, GSK gained 0.4% market share with an evolution index of 104-plus.
- Stewardship as a moat: India in 2025 has one of the highest susceptibility rates (90%-93%) to Co-amoxiclav, which management attributes to appropriate usage and efforts to avoid antimicrobial resistance; GSK works with specialists and GPs through the India Infection Index to ensure antibiotics are chosen wisely for the right indication.
Margins & Expense Phasing
- EBITDA margin walk: Margin improved 290 bps to 31.2% despite a flat topline, driven by better expense management and productivity improvement; PAT grew 12.7%, following the same trend.
- Other expenses drop explained: The 17% drop in other expenses is largely phasing: close to Rs. 12-13 crores of advertising and promotional spend was moved to Q2-Q3 to align with peak season and monsoon-driven sales.
- Margin outlook stable: Management expects to maintain margin levels; price increases will flow in coming quarters, but increased expenses will also come due to phasing, keeping margins steady.
- Innovative product margin dilution contained: Margins from innovative products are lower than general medicines, but as the larger general medicines base grows, absolute margin will be maintained; management sees no margin dilution over at least the next 2-3 years.
Juby Chandy: "But that said, as the general medicines portfolio grows, we will be able to maintain that absolute margin and the impact on the margin dilution will take a little bit longer term to see. At least in the next 2-3 years, we will not see a dilution in the margins because the ratio at which that grows, the general medicine, the larger base grows, we will dilute any margin dilution we would see from the above."
Trade Generics & Regulatory Landscape
- Trade generics impact estimate: Per management, trade generics are expected to impact volumes by 5%-7% initially, rising to 7%-10% over the next three years.
- MFN price rule exposure minimal: Management sees no impact from MFN price requirements because most products are manufactured locally and imported products do not originate from the US.
- Salesforce commitment: GSK will continue to maintain the current representative count of more than 2,000.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Oncology revenue start | Zejula and Jemperli revenue begins reflecting in financials | Q2 FY26 |
| Derm business recovery | Volume growth expected back in derm portfolio | Q2 FY26 |
| NLEM price hike realization | Full benefit of price hikes flows through | Q2 FY26 and beyond |
| Calpol supply normalization | Supply stabilized from affected CMO | July-August 2025 |
| Margin dilution protection | No dilution in margins from innovative product mix | At least next 2-3 years |
| RSV vaccine launch | Launch in India | Calendar year 2026 |
| EBITDA margin maintenance | Confident of holding current margin levels | Ongoing |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue growth | Flat, softer than expected tailwinds in antibiotics and derma portfolio |
| EBITDA margin | 31.2%, 290 bps improvement YoY with 9.3% growth |
| PAT growth | 12.7% YoY, stepped up 290 bps |
| EPS | ₹12.08, 13% growth YoY |
| Cash conversion | 100% of sales for the quarter converted to cash |
| Overall price hike | 2.83% (including vaccines) |
| Vaccines value growth | 8.6% YoY |
| General medicines value growth | Negative 2% YoY |
| Revenue impact from CMO fire | 1.7% of sales lost; underlying growth 1.7% excluding this |
| NLEM portfolio share | ~40% of portfolio |
| Shingrix monthly doses | ~9,000-10,000 doses per month, private self-pay segment |
| Shingrix annual target | In excess of 100,000 doses, translating to over ₹100 cr |
| Oncology sales force | ~20 key account specialists, targeting ~1,200 medical oncologists and ~500 dermatologists |
| Omni-channel reach | 4.6 lakh doctors with consent, up from ~3 lakh before digital acceleration |
| Sourcing from GSK Nashik facility | 35%-40%; remaining 60% from CMOs |